Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03624127 · ClinicalTrials.gov registry record · Phase 3
Effectiveness and Safety of BMS-986165 Compared to Placebo and Active Comparator in Participants With Psoriasis
A Phase 3 study, sponsored by Bristol-Myers Squibb.
- Completed
- Registry status
- Phase 3
- Development phase
- 666
- Enrollment target
NCT03624127 is a Phase 3 study that has completed, run by Bristol-Myers Squibb. The registered enrollment target is 666 participants.
The verdict
NCT03624127, a Phase 3 study, has completed, sponsored by Bristol-Myers Squibb.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 666 participants
- Enrollment target
Study Summary
The purpose of this study is to investigate the experimental medication BMS-986165 compared to placebo and a currently available treatment in participants with moderate to severe plaque psoriasis.
Interventions
- OTHER Placebo
- DRUG Apremilast
- DRUG BMS-986165
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 666 participants |
| Start Date | 2018-08-07 |
| Est. Completion | 2020-09-02 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03624127
The ClinicalTrials.gov registry entry for NCT03624127 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 666 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bristol-Myers Squibb, which has 1,025 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT03624127 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03624127 about?
NCT03624127 is a clinical study titled "Effectiveness and Safety of BMS-986165 Compared to Placebo and Active Comparator in Participants With Psoriasis". The purpose of this study is to investigate the experimental medication BMS-986165 compared to placebo and a currently available treatment in participants with moderate to severe plaque psoriasis.
What is the current status of trial NCT03624127?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 666 participants. The study started on 2018-08-07. Estimated completion is 2020-09-02.
What interventions are being tested in trial NCT03624127?
The interventions under investigation include: Placebo (OTHER), Apremilast (DRUG), BMS-986165 (DRUG).
Who is sponsoring clinical trial NCT03624127?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.